Is Canafenib included in medical insurance? The latest medical insurance policies and reimbursement conditions in 2025

Encorafenib is an oral small molecule BRAF kinase inhibitor, mainly used to treat patients with unresectable or metastatic melanoma and non-small cell lung cancer (NSCLC) carrying BRAF V600E or V600K mutations. It is often used in combination with bimetinib (Binimetinib) to enhance the therapeutic effect. In addition, canafenib can also be combined with cetuximab (Cetuximab) for the treatment of patients with metastatic colorectal cancer (CRC) carrying BRAF V600E mutations. It prevents the growth and spread of cancer cells by inhibiting the signaling pathways related to BRAF mutations. It should be noted that canafenib is not indicated for the treatment of patients with wild-type BRAF melanoma or colorectal cancer.

As of now, Canafenib has not been officially launched in mainland China. Therefore, this drug has not yet been included in China's National Medical Insurance List. This means that if patients need to use canafenib, they may need to obtain it through overseas medical channels and bear the cost themselves. However, with the sharing of global medical resources and the acceleration of China's drug approval process, the possibility that canafenib will be launched in China and included in medical insurance in the future is increasing. Patients and their families are advised to pay close attention to the latest announcements from the National Medical Products Administration and the National Medical Insurance Administration to obtain the latest drug marketing and medical insurance policy information.

While waiting for canafenib to officially enter the Chinese market, patients should discuss possible treatment options with their attending doctors, including existing targeted therapy, chemotherapy or other suitable treatments. At the same time, learning about and participating in clinical trials is also a way, which may provide new treatment opportunities for patients. In short, paying close attention to the progress of drug launches and changes in medical insurance policies, and actively communicating with the medical team are important steps for patients to obtain the best treatment results.

Reference materials:https://www.braftovi.com/